Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Goodwill: 2013-2024

Historic Goodwill for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Dec 2024 value amounting to $3.0 million.

  • Amphastar Pharmaceuticals' Goodwill rose 4.55% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year increase of 4.55%. This contributed to the annual value of $3.0 million for FY2024, which is 5.19% down from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Goodwill stood at $3.0 million for FY2024, which was down 5.19% from $3.2 million recorded in FY2023.
  • Amphastar Pharmaceuticals' Goodwill's 5-year high stood at $3.9 million during FY2020, with a 5-year trough of $3.0 million in FY2024.
  • For the 3-year period, Amphastar Pharmaceuticals' Goodwill averaged around $3.1 million, with its median value being $3.1 million (2022).
  • Per our database at Business Quant, Amphastar Pharmaceuticals' Goodwill rose by 8.42% in 2020 and then fell by 15.91% in 2021.
  • Amphastar Pharmaceuticals' Goodwill (Yearly) stood at $3.9 million in 2020, then declined by 15.91% to $3.3 million in 2021, then declined by 5.64% to $3.1 million in 2022, then grew by 2.88% to $3.2 million in 2023, then dropped by 5.19% to $3.0 million in 2024.